查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999304

豬隻疫苗市場：2026-2032年全球市場預測（依疫苗類型、動物年齡、給藥途徑、包裝、最終用戶、疾病類型及通路分類）

Swine Vaccines Market by Vaccine Type, Animal Age, Route Of Administration, Packaging Type, End User, Disease Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，豬疫苗市場價值將達到 17 億美元，到 2026 年將成長到 18.4 億美元，到 2032 年將達到 29.9 億美元，複合年成長率為 8.34%。

主要市場統計數據
基準年 2025 17億美元
預計年份：2026年 18.4億美元
預測年份：2032年 29.9億美元
複合年成長率 (%) 8.34%

本書全面概述了現代豬疫苗接種策略如何在不斷發展的全球供應鏈中支持豬群健康、生產韌性和農場層面的生物安全。

豬疫苗的現狀在動物健康、食品安全和農業經濟的交匯點上發揮著至關重要的作用。在現代生豬生產系統中，疫苗接種已從偶爾的干涉措施發展成為豬群健康計畫不可或缺的一部分，旨在保護生產力、動物福利以及公眾對供應鏈的信心。集約化養殖、國際貿易以及病毒和細菌病原體的出現和再次出現所帶來的日益成長的壓力，進一步凸顯了製定強力的預防策略的必要性。因此，疫苗不再只是生物安全工具，而是直接影響農場韌性、合理使用抗生素和長期永續性的戰略資產。

科技、監管和商業的變革如何結合起來，將疫苗轉變為能夠增強畜群健康韌性和營運效率的綜合解決方案？

過去五年，隨著技術、監管和商業動態的融合，豬隻疫苗生態系統經歷了快速轉型，並重塑了產業的格局。在技​​術層面，新型抗原平台和佐劑技術的進步提高了疫苗的預防效力，同時減少了副作用，並增強了疫苗與豬群日常管理操作的兼容性。同時，給藥途徑和包裝方式的改進降低了操作的複雜性，並為大規模養豬場的群體免疫接種提供了更多實際選擇。此外，病原體監測投入的增加也進一步鞏固了這些創新成果，提高了疫苗株選擇的準確性，並縮短了從發現病原體到採取針對性免疫措施的時間。

評估 2025 年關稅措施對豬隻疫苗供應鏈和產業韌性的連鎖影響，包括營運、採購和監管方面。

近期公佈的2025年關稅措施為豬疫苗供應鏈中的相關人員帶來了新的挑戰，影響到原料、成品以及跨境合作。這些關稅改變了進口零件和成品疫苗的實際成本結構，迫使生產商和代工生產商重新評估其籌資策略和短期生產分配。在許多情況下，這些調整加速了特定生產流程的在地化進程，並促使企業擺脫對單一國家的依賴，實現採購來源多元化。同時，經銷商和出口型供應商在跨境物流方面面臨日益加劇的摩擦，這需要重新談判商業條款並採取更靈活的庫存管理策略。

對疫苗平台、動物年齡層、給藥途徑、包裝、目標疾病、最終用戶和分銷管道進行詳細的細分洞察，對於有針對性的商業化非常有用。

對細分市場的詳細分析揭示了疫苗類型、動物年齡層、給藥途徑、包裝、最終用戶、目標疾病和分銷管道等方面的不同趨勢，每種因素都對產品開發和商業化產生獨特的影響。疫苗類型包括DNA疫苗、去活化疫苗、減毒活病毒疫苗、重組疫苗、次單位疫苗疫苗和類毒素疫苗，每種疫苗都有其獨特的風險效益比，影響整個生產系統的應用。動物年齡層包括種豬、肥育豬、生長豬、小豬和離乳仔豬。種豬進一步細分為公豬和母豬，並制定了特定的免疫接種時間和給藥策略，以保護其繁殖能力和仔豬健康。

區域比較分析揭示了北美和南美、歐洲、中東和非洲以及亞太地區的市場如何尋求個人化的疫苗開發、分銷和監管策略。

豬疫苗領域的區域趨勢在成熟生產區和新興成長市場之間存在顯著差異，這影響著產品設計、監管合作和打入市場策略的優先事項。在美洲，高密度生產系統和一體化商業農場推動了對可擴展疫苗解決方案的需求，這些方案旨在最佳化勞動效率和群體免疫力。在該地區，穩健的供應鏈、可預測的監管流程以及與行業和獸醫的緊密聯繫對於支持檢驗的創新疫苗的快速推廣至關重要。

主要企業如何平衡平台創新、製造能力和策略夥伴關係，以確保競爭優勢並加速產品推廣？

主要企業正以差異化的策略進軍豬隻疫苗市場，這些策略體現了其產品組合的專業化、地理重點和生技藥品生產能力。一些企業優先考慮平台多元化，並投資於新一代抗原技術和佐劑系統，以擴大對多種病原體的保護範圍，同時減少不利事件。另一些企業則專注於創新給藥途徑和改進包裝，以降低大規模商業營運中的給藥複雜性和產品浪費。製造商與獸醫服務提供者之間的策略合作有助於彌合「最後一公里」差距，並透過將培訓、診斷支援和現場監測整合到商業服務中，促進疫苗的推廣應用。

為產業領導者提供切實可行的策略和營運建議，以加強養豬系統中的疫苗創新、供應韌性和分銷。

行業領導者應採取多管齊下的策略，將科學創新與切實可行的商業和營運措施相結合，以加強疫苗分發和市場韌性。首先，優先投資於能夠提供廣泛保護並快速適應新出現的病毒株的平台技術，將帶來永續的競爭優勢。除了研發重點外，還應有針對性地改進給藥方法和包裝，以減少現場操作的阻力，並支持大規模疫苗宣傳活動。

對混合方法研究方法進行了透明的概述，該方法整合了初步訪談、文獻整合、細分映射和專家檢驗，以得出可操作的見解。

本分析所依據的研究結合了定性和定量方法，以確保對整個疫苗價值鏈進行全面而深入的洞察。主要研究包括對獸醫、農場管理者、生產商、經銷商和監管專家進行結構化訪談，以了解他們的實務經驗和策略重點。次要研究則包括科學文獻、監管指南、專利申請和生產系統分析的系統性回顧，以闡明技術和政策趨勢的背景。這些資訊透過三角測量法進行整合，該方法結合了不同的觀點並檢驗了新出現的主題。

簡明扼要地闡述了將疫苗創新與豬隻健康和生產韌性的持續改善聯繫起來所需的策略重點和協作努力。

疫苗接種仍然是保護豬隻健康、維持生產連續性、增強大眾對豬肉供應鏈信心的最有效、最可推廣的手段。目前，豬肉產業正處於轉折點，科學進步、貿易環境變化以及畜牧養殖戶實踐的演變都要求生產者、獸醫和政策制定者採取協調一致的應對措施。成功的關鍵在於將創新研發與切實可行的實施機制結合，加強地方層級的生產和供應韌性，並深化夥伴關係，將科學進步轉化為日常畜群管理實踐。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：豬疫苗市場：依疫苗類型分類

  • DNA疫苗
  • 去活化疫苗
  • 減毒活病毒疫苗
  • 重組疫苗
  • 次單位疫苗
  • 類毒素疫苗

第9章：豬疫苗市場：依動物年齡層別分類

  • 種豬
    • 種豬
    • 母豬
  • 肥育豬
  • 生長豬
  • 小豬
  • 斷奶仔豬

第10章：豬隻疫苗市場：依給藥途徑分類

  • 注射
  • 鼻內
  • 口服

第11章：豬疫苗市場：依包裝類型分類

  • 多劑量瓶
  • 預填充式注射器
  • 管瓶

第12章：豬疫苗市場：依最終用戶分類

  • 商業農場
  • 研究機構
  • 動物診所
  • 動物醫院

第13章：豬疫苗市場：依疾病類型分類

  • 經典豬瘟
  • 斑疹熱
  • 肺炎黴漿菌
  • 豬環狀病毒
  • 豬繁殖與呼吸綜合症
  • 豬流感

第14章：豬隻疫苗市場：依通路分類

  • 網路藥房
    • 企業網站
    • EC平台
  • 動物診所
  • 動物醫院

第15章：豬疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：豬疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 豬疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國豬疫苗市場

第19章：中國豬疫苗市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bimeda Holdings plc
  • Biogenesis Bago SA
  • Biovac Ltd.
  • Bioveta, as
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • China Animal Husbandry Industry Co., Ltd.
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • HIPRA Laboratories, SA
  • Hygieia Biological Laboratories（private company）
  • IDT Biologika GmbH
  • Indian Immunologicals Limited
  • Intervet Inc.
  • Jinyu Bio-Technology Co., Ltd.
  • KM Biologics Co., Ltd.
  • Komipharm International Co., Ltd.
  • Kyoritsu Seiyaku Corporation
  • Lohmann Animal Health International GmbH & Co. KG
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-3A2E844FD486

The Swine Vaccines Market was valued at USD 1.70 billion in 2025 and is projected to grow to USD 1.84 billion in 2026, with a CAGR of 8.34%, reaching USD 2.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.70 billion
Estimated Year [2026] USD 1.84 billion
Forecast Year [2032] USD 2.99 billion
CAGR (%) 8.34%

A compelling overview of how modern swine vaccination strategies underpin herd health, production resilience, and farm-level biosecurity across evolving global supply chains

The swine vaccines landscape occupies a pivotal role at the intersection of animal health, food security, and agricultural economics. In modern pork production systems, vaccination has evolved from an occasional intervention into an integral component of herd health programs that safeguard productivity, animal welfare, and public confidence in supply chains. Growing pressures from intensification, global trade, and the emergence and re-emergence of viral and bacterial pathogens have sharpened the need for robust preventive strategies. As a result, vaccines are not merely biosecurity tools but strategic assets that directly influence farm resilience, antimicrobial stewardship, and long-term sustainability.

Beyond farm gates, the vaccine value chain comprises manufacturers, distributors, veterinarians, diagnostic providers, and regulatory authorities whose interactions determine how rapidly innovations translate into field impact. The convergence of advanced molecular platforms, improved delivery systems, and digital health tools is enabling more targeted immunization approaches. At the same time, demographic shifts in producer profiles, consolidation among commercial farms, and shifting consumer expectations create a complex operating environment. Consequently, stakeholders must balance immediate operational demands with mid- to long-term investments in research, cold-chain logistics, and training to realize the full potential of vaccination as a cornerstone of modern swine health management.

How converging technological, regulatory, and commercial shifts are transforming vaccines into integrated solutions that enhance herd health resilience and operational efficiency

The past five years have witnessed accelerated change in the swine vaccines ecosystem as technological, regulatory, and commercial dynamics converge to reshape industry boundaries. On the technological front, novel antigen platforms and adjuvant science have advanced protective performance while reducing adverse reactions and improving compatibility with herd management routines. Parallel developments in administration routes and packaging have lowered handling complexity and expanded practical options for mass immunization in large-scale operations. These innovations have been reinforced by increasing investment in pathogen surveillance, which improves the precision of vaccine strain selection and shortens the time from detection to targeted response.

Commercially, strategic partnerships and targeted investments in manufacturing capacity have improved responsiveness to regional demand fluctuations and supply interruptions. Regulatory agencies have moved toward clearer guidance on safety evaluation and field efficacy, encouraging more rigorous post-market surveillance and harmonized standards across jurisdictions. Meanwhile, digitalization-ranging from cold-chain telemetry to herd-level vaccine compliance tracking-has enhanced traceability and decision support for veterinarians and farm managers. Collectively, these shifts are transforming vaccines from single-product transactions into integrated solutions that combine scientific innovation, operational support, and data-driven insights to secure herd health at scale.

Assessment of the cascading operational, sourcing, and regulatory consequences that 2025 tariff actions have imposed on swine vaccine supply chains and industry resilience

Recent tariff measures announced in 2025 have introduced a new layer of complexity for stakeholders in the swine vaccines supply chain, affecting inputs, finished products, and cross-border collaboration. As tariffs alter the effective cost structure for imported components and finished doses, manufacturers and contract producers have had to reassess sourcing strategies and near-term manufacturing allocations. In many cases, the adjustments have accelerated efforts to localize certain production steps or to diversify procurement away from single-country dependencies. At the same time, distributors and export-oriented suppliers face elevated friction in cross-border logistics, necessitating renegotiated commercial terms and more dynamic inventory management.

These trade shifts have implications beyond immediate cost and logistics. They have increased the strategic value of regional regulatory alignment and mutual recognition agreements that reduce duplication of conformity assessments. In response, several firms have intensified engagement with regional authorities to streamline approvals and maintain uninterrupted access to essential biological inputs. From a research perspective, tariff-driven complexity has also encouraged closer collaboration between domestic manufacturers and academic institutions to insulate vaccine pipelines from international volatility. For end users, the net effect has been a renewed focus on resilience: producers are prioritizing vaccine regimens that minimize administration frequency and simplify handling, while veterinarians and supply partners emphasize robust contingency planning to sustain immunization programs amid shifting trade conditions.

Detailed segmentation insights across vaccine platforms, animal age classes, administration routes, packaging configurations, disease targets, end users, and distribution channels informing targeted commercialization

A granular look at segmentation reveals differentiated dynamics across vaccine type, animal age category, administration route, packaging format, end user, disease focus, and distribution channels, each with distinct implications for product development and commercialization. Vaccine type diversity spans DNA vaccine, inactivated vaccine, live attenuated vaccine, recombinant vaccine, subunit vaccine, and toxoid vaccine platforms, and each platform presents a unique risk-benefit profile that influences adoption across production systems. Animal age segments include breeders, finishers, growers, piglets, and weaners, with breeders further differentiated into boars and sows, creating specific immunization windows and dosing strategies to protect reproductive performance as well as piglet health.

Administration route choices-between injection, nasal, and oral delivery-affect labor requirements, stress on animals, and opportunities for mass vaccination. Packaging type options, including multi dose bottle, pre filled syringe, and vial formats, determine cold-chain demands, wastage rates, and field usability. End users range from commercial farms to research institutes, veterinary clinics, and veterinary hospitals, and each category has different purchasing behaviors, compliance expectations, and technical capabilities. Disease-focused segmentation covers classical swine fever, erysipelas, mycoplasma pneumonia, porcine circovirus, porcine reproductive and respiratory syndrome, and swine influenza; vaccines targeted at these conditions vary in immunogenic profile and regulatory pathway complexity. Distribution channels include online pharmacies, veterinary clinics, and veterinary hospitals, with online pharmacies further segmented into company websites and e-commerce platforms, a distinction that influences marketing, fulfillment, and after-sales support strategies. Together, these segmentation lenses enable a more nuanced approach to prioritizing R&D investments, tailoring messaging, and aligning commercial models with end-user realities.

Comparative regional analysis clarifying how the Americas, Europe Middle East & Africa, and Asia-Pacific markets demand tailored vaccine development, distribution, and regulatory strategies

Regional dynamics in the swine vaccines arena differ markedly across established production zones and emerging growth markets, shaping priorities for product design, regulatory engagement, and market access strategies. In the Americas, high-intensity production systems and integrated commercial farms drive demand for scalable vaccination solutions that optimize labor efficiency and herd-level immunity. This region places a premium on robust supply chains, predictable regulatory processes, and strong industry-veterinarian relationships that support rapid uptake of validated vaccine innovations.

In Europe, Middle East & Africa, regulatory complexity and diverse production models create both challenges and opportunities. Western European markets emphasize stringent safety and pharmacovigilance standards, while segments in Eastern Europe, the Middle East, and Africa often require cost-effective formulations and packaging that accommodate smaller-scale operations and variable cold-chain infrastructure. This heterogeneity encourages modular strategies that combine high-efficacy platforms with adaptive delivery and packaging options. In the Asia-Pacific region, dense production hubs and recurring disease pressures accelerate adoption of novel vaccine technologies and mass-administration approaches. The rapid expansion of contract manufacturing and growing capabilities in local R&D institutions have made the region a focal point for both innovation and regional supply security. Across all regions, digital distribution channels and e-commerce are emerging as complementary pathways to reach veterinary professionals and farm managers, particularly where traditional distribution networks face structural constraints.

How leading industry players are balancing platform innovation, manufacturing capacity, and strategic partnerships to secure competitive advantage and accelerate product adoption

Leading corporate participants approach the swine vaccines space with differentiated strategies that reflect portfolio specialization, geographic focus, and capabilities in biologics manufacturing. Some firms prioritize platform diversification, investing in next-generation antigen technologies and adjuvant systems to broaden protection across multiple pathogens while reducing adverse events. Other organizations concentrate on route-of-administration innovations and packaging improvements to lower administration complexity and product wastage in large-scale commercial operations. Strategic alliances between manufacturers and veterinary service providers help bridge the final-mile gap and strengthen adoption by integrating training, diagnostic support, and field monitoring into commercial offerings.

Manufacturing scale and the ability to meet stringent quality standards are central competitive levers, as are flexible contract manufacturing arrangements that enable rapid capacity scaling. Intellectual property management and a disciplined approach to regulatory submissions determine how quickly new vaccines can be commercialized across regions with divergent approval timelines. Finally, an increasing number of companies are pursuing collaborative research with academic centers and public veterinary institutes to accelerate translational studies while sharing development risk. These combined approaches underscore that success in the sector depends on a balanced emphasis across R&D, manufacturing excellence, regulatory strategy, and commercial execution.

Practical strategic and operational recommendations that industry leaders can implement to enhance vaccine innovation, supply resilience, and adoption in swine production systems

Industry leaders should adopt a multi-pronged playbook that aligns scientific innovation with pragmatic commercial and operational measures to strengthen vaccine uptake and market resilience. First, prioritizing investments in platform technologies that enable broad-spectrum protection and rapid adaptability to emerging strains will yield durable competitive advantages. Complementing that R&D focus with targeted improvements in administration methods and packaging will reduce field friction and support mass vaccination campaigns.

Second, building more resilient sourcing and manufacturing strategies is essential. This includes diversifying key input suppliers, expanding regional manufacturing footprints, and using flexible contract manufacturing relationships to maintain continuity in times of trade disruption. Third, proactive regulatory engagement can shorten time-to-field by clarifying data expectations and leveraging harmonized approval pathways where available. Fourth, companies should expand partnerships with veterinarians and farm service providers to embed vaccination into comprehensive herd health programs that include diagnostics, data analytics, and training. Finally, investing in digital tools for supply-chain visibility, cold-chain monitoring, and compliance tracking will improve operational reliability and provide actionable data to optimize immunization outcomes. These steps, taken together, form an actionable roadmap to enhance product relevance, commercial traction, and farm-level impact.

Transparent overview of the mixed-method research approach that integrated primary interviews, literature synthesis, segmentation mapping, and expert validation to derive actionable insights

The research underpinning this analysis combined qualitative and quantitative techniques to ensure robust, triangulated insights across the vaccine value chain. Primary research included structured interviews with veterinarians, farm managers, manufacturers, distributors, and regulatory specialists to capture frontline experience and strategic priorities. Secondary research involved systematic review of scientific literature, regulatory guidance, patent filings, and production system analyses to contextualize technological and policy trends. These inputs were synthesized using a triangulation approach that reconciled disparate perspectives and validated emerging themes.

Segmentation mapping was applied to align product attributes with end-user needs, administration realities, and distribution pathways. A cross-validation stage incorporated independent expert review panels to challenge assumptions and refine recommendations. Methodological limitations were addressed by documenting data gaps and uncertainty ranges, and by emphasizing qualitative implications where quantitative precision was constrained. Ethical considerations and confidentiality protocols guided interview conduct and the anonymization of proprietary information. Together, these methods produced a defensible and actionable evidence base designed to inform decision-making across R&D, manufacturing, regulatory, and commercial domains.

Concise synthesis highlighting the strategic priorities and coordinated actions necessary for translating vaccine innovation into sustained improvements in swine health and production resilience

Vaccination remains the most effective and scalable tool to protect swine health, preserve production continuity, and support public confidence in the pork supply chain. The industry stands at an inflection point where scientific progress, shifting trade dynamics, and changing farm practices demand coordinated responses from manufacturers, veterinarians, and policy makers. Success will depend on aligning innovation pipelines with practical delivery mechanisms, strengthening regional manufacturing and supply resilience, and deepening partnerships that translate scientific advances into routine herd-level practices.

In the short term, stakeholders should focus on operational measures that preserve continuity-diversifying suppliers, optimizing inventory strategies, and improving cold-chain oversight. In the medium term, investments in adaptable vaccine platforms, streamlined regulatory strategies, and expanded field support capabilities will determine which organizations lead in both developed and emerging markets. Ultimately, the capacity to convert technical superiority into accessible, implementable solutions for diverse end users will define market leadership and, more importantly, drive measurable improvements in animal health and farm sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Swine Vaccines Market, by Vaccine Type

  • 8.1. Dna Vaccine
  • 8.2. Inactivated Vaccine
  • 8.3. Live Attenuated Vaccine
  • 8.4. Recombinant Vaccine
  • 8.5. Subunit Vaccine
  • 8.6. Toxoid Vaccine

9. Swine Vaccines Market, by Animal Age

  • 9.1. Breeders
    • 9.1.1. Boars
    • 9.1.2. Sows
  • 9.2. Finishers
  • 9.3. Growers
  • 9.4. Piglets
  • 9.5. Weaners

10. Swine Vaccines Market, by Route Of Administration

  • 10.1. Injection
  • 10.2. Nasal
  • 10.3. Oral

11. Swine Vaccines Market, by Packaging Type

  • 11.1. Multi Dose Bottle
  • 11.2. Pre Filled Syringe
  • 11.3. Vial

12. Swine Vaccines Market, by End User

  • 12.1. Commercial Farms
  • 12.2. Research Institutes
  • 12.3. Veterinary Clinics
  • 12.4. Veterinary Hospitals

13. Swine Vaccines Market, by Disease Type

  • 13.1. Classical Swine Fever
  • 13.2. Erysipelas
  • 13.3. Mycoplasma Pneumonia
  • 13.4. Porcine Circovirus
  • 13.5. Porcine Reproductive And Respiratory Syndrome
  • 13.6. Swine Influenza

14. Swine Vaccines Market, by Distribution Channel

  • 14.1. Online Pharmacies
    • 14.1.1. Company Websites
    • 14.1.2. E Commerce Platforms
  • 14.2. Veterinary Clinics
  • 14.3. Veterinary Hospitals

15. Swine Vaccines Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Swine Vaccines Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Swine Vaccines Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Swine Vaccines Market

19. China Swine Vaccines Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Bimeda Holdings plc
  • 20.6. Biogenesis Bago S.A.
  • 20.7. Biovac Ltd.
  • 20.8. Bioveta, a.s.
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Ceva Sante Animale SA
  • 20.11. China Animal Husbandry Industry Co., Ltd.
  • 20.12. Elanco Animal Health Incorporated
  • 20.13. Hester Biosciences Limited
  • 20.14. HIPRA Laboratories, S.A.
  • 20.15. Hygieia Biological Laboratories (private company)
  • 20.16. IDT Biologika GmbH
  • 20.17. Indian Immunologicals Limited
  • 20.18. Intervet Inc.
  • 20.19. Jinyu Bio-Technology Co., Ltd.
  • 20.20. KM Biologics Co., Ltd.
  • 20.21. Komipharm International Co., Ltd.
  • 20.22. Kyoritsu Seiyaku Corporation
  • 20.23. Lohmann Animal Health International GmbH & Co. KG
  • 20.24. Merck & Co., Inc.
  • 20.25. Phibro Animal Health Corporation
  • 20.26. Vetoquinol S.A.
  • 20.27. Virbac S.A.
  • 20.28. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SWINE VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SWINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SWINE VACCINES MARKET SIZE, BY DNA VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SWINE VACCINES MARKET SIZE, BY DNA VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SWINE VACCINES MARKET SIZE, BY DNA VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SWINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SWINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SWINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SWINE VACCINES MARKET SIZE, BY TOXOID VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SWINE VACCINES MARKET SIZE, BY TOXOID VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SWINE VACCINES MARKET SIZE, BY TOXOID VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SWINE VACCINES MARKET SIZE, BY BOARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SWINE VACCINES MARKET SIZE, BY BOARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SWINE VACCINES MARKET SIZE, BY BOARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SWINE VACCINES MARKET SIZE, BY SOWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SWINE VACCINES MARKET SIZE, BY SOWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SWINE VACCINES MARKET SIZE, BY SOWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SWINE VACCINES MARKET SIZE, BY FINISHERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SWINE VACCINES MARKET SIZE, BY FINISHERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SWINE VACCINES MARKET SIZE, BY FINISHERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SWINE VACCINES MARKET SIZE, BY GROWERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SWINE VACCINES MARKET SIZE, BY GROWERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SWINE VACCINES MARKET SIZE, BY GROWERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SWINE VACCINES MARKET SIZE, BY PIGLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SWINE VACCINES MARKET SIZE, BY PIGLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SWINE VACCINES MARKET SIZE, BY PIGLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SWINE VACCINES MARKET SIZE, BY WEANERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SWINE VACCINES MARKET SIZE, BY WEANERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SWINE VACCINES MARKET SIZE, BY WEANERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SWINE VACCINES MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SWINE VACCINES MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SWINE VACCINES MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SWINE VACCINES MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SWINE VACCINES MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SWINE VACCINES MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SWINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SWINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SWINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SWINE VACCINES MARKET SIZE, BY MULTI DOSE BOTTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SWINE VACCINES MARKET SIZE, BY MULTI DOSE BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SWINE VACCINES MARKET SIZE, BY MULTI DOSE BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SWINE VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SWINE VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SWINE VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SWINE VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SWINE VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SWINE VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SWINE VACCINES MARKET SIZE, BY COMMERCIAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SWINE VACCINES MARKET SIZE, BY COMMERCIAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SWINE VACCINES MARKET SIZE, BY COMMERCIAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SWINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SWINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SWINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SWINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SWINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SWINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SWINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SWINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SWINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SWINE VACCINES MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SWINE VACCINES MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SWINE VACCINES MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SWINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SWINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SWINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SWINE VACCINES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SWINE VACCINES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SWINE VACCINES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SWINE VACCINES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SWINE VACCINES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SWINE VACCINES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS SWINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. GCC SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. GCC SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GCC SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. G7 SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. G7 SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. NATO SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. NATO SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)